Skip to main content
Top

16-05-2024 | Nevi | Hepatobiliary

Effectiveness of deep learning-based reconstruction for improvement of image quality and liver tumor detectability in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging

Authors: Yukihisa Takayama, Keisuke Sato, Shinji Tanaka, Ryo Murayama, Ryotaro Jingu, Kengo Yoshimitsu

Published in: Abdominal Radiology

Login to get access

Abstract

Purpose

To evaluate the effectiveness of deep learning-based reconstruction (DLR) in improving image quality and tumor detectability of isovoxel high-resolution breath-hold fat-suppressed T1-weighted imaging (HR-BH-FS-T1WI) in the hepatobiliary phase (HBP) of Gadoxetic acid-enhanced magnetic resonance imaging (Gd-EOB-MRI).

Materials and methods

This retrospective evaluated 42 patients with 98 liver tumors who underwent Gd-EOB-MRI between March 2023 and May 2023 using three techniques based on HBP imaging: isovoxel HR-BH-FS-T1WI reconstructed (1) with DLR (BH-DLR +) and (2) without DLR (BH-DLR −) and (3) HR-FS-T1WI scanned with a free-breathing technique using a navigator-echo-triggered technique and DLR (Navi-DLR +). The three techniques were qualitatively and quantitatively compared by the Friedman test and the Bonferroni post-hoc test. Tumor detectability was compared using the McNemar test.

Results

BH-DLR + (3.85, average score of two radiologists) showed significantly better qualitative scores for image noise than BH-DLR − (2.84) and Navi-DLR + (3.37) (p < 0.0167), and Navi-DLR + showed significantly better scores than BH-DLR − (p < 0.0167). BH-DLR + (3.77) and BH-DLR − (3.77) showed significantly better qualitative scores for respiratory motion artifact than Navi-DLR + (2.75) (p < 0.0167), but there was no significant difference in scores between BH-DLR + and BH-DLR − (p > 0.0167). BH-DLR + (0.32) and Navi-DLR + (0.33) showed significantly higher lesion-to-nonlesion CR than BH-DLR − (0.29) (p < 0.0167), but there was no significant difference in lesion-to-nonlesion CR between BH-DLR + and Navi-DLR + (p > 0.0167). BH-DLR + (89.8%) showed significantly better tumor detectability than BH-DLR − (76.0%) and Navi-DLR + (77.6%) (p < 0.05).

Conclusion

The use of DLR for isovoxel HR-BH-FS-T1WI was effective in improving image quality and tumor detectability.

Graphical abstract

Literature
10.
26.
go back to reference Takayama Y, Nishie A, Okamoto D, Fujita N, Asayama Y, Ushijima Y, et al. Differentiating Liver Hemangioma from Metastatic Tumor Using T2-enhanced Spin-echo Imaging with a Time-reversed Gradient-echo Sequence in the Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging. Magn Reson Med Sci. 2022;21(3):445-57. doi: https://doi.org/10.2463/mrms.mp.2020-0151.CrossRefPubMed Takayama Y, Nishie A, Okamoto D, Fujita N, Asayama Y, Ushijima Y, et al. Differentiating Liver Hemangioma from Metastatic Tumor Using T2-enhanced Spin-echo Imaging with a Time-reversed Gradient-echo Sequence in the Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging. Magn Reson Med Sci. 2022;21(3):445-57. doi: https://​doi.​org/​10.​2463/​mrms.​mp.​2020-0151.CrossRefPubMed
Metadata
Title
Effectiveness of deep learning-based reconstruction for improvement of image quality and liver tumor detectability in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging
Authors
Yukihisa Takayama
Keisuke Sato
Shinji Tanaka
Ryo Murayama
Ryotaro Jingu
Kengo Yoshimitsu
Publication date
16-05-2024
Publisher
Springer US
Published in
Abdominal Radiology
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-024-04374-w

A quick guide to ECGs

Electrocardiography Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

Obesity Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more